Developing New Ocular Therapies that Help Patients See Their Very Best Throughout Their Lives

PanOptica, Inc., is a private, clinical-stage biopharmaceutical company focused on developing a topical eye drop for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. These neovascular eye diseases include neovascular age-related macular degeneration (wet AMD), the leading cause of blindness in the Western world, and diabetic retinopathy.

Year Invested: 2010
Location: Bernardsville, NJ

Recent News

May 22, 2018
PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial

October 6, 2017
PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 - a Novel, Topical Anti-VEGF Eye Drop

October 14, 2016
PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop

Read More News

Associated Team Members

Kevin Starr

Abbie Celniker, Ph.D.